drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive immunotherapy)
drug_description
Genetically engineered T cells expressing a chimeric antigen receptor targeting malignant B cells; infused 2–10×10^6/kg within 7 days post-ASCT.
nci_thesaurus_concept_id
C200766
nci_thesaurus_definition
Autologous T-lymphocytes engineered to contain one or more chimeric antigen receptors (CARs) that specifically target one or more specific antigen(s).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that recognizes B‑cell tumor antigens (e.g., CD19) independently of HLA, providing CD3ζ plus co‑stimulatory signaling (e.g., CD28 or 4‑1BB) to activate and expand the cells, leading to cytokine release and perforin/granzyme‑mediated cytotoxic killing of malignant B cells.
drug_name
Autologous CAR-T cells
nct_id_drug_ref
NCT06381830